199 related articles for article (PubMed ID: 19417159)
1. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.
Feng Y; Xiao X; Zhu Z; Streaker E; Ho M; Pastan I; Dimitrov DS
Mol Cancer Ther; 2009 May; 8(5):1113-8. PubMed ID: 19417159
[TBL] [Abstract][Full Text] [Related]
2. A novel high-affinity human monoclonal antibody to mesothelin.
Ho M; Feng M; Fisher RJ; Rader C; Pastan I
Int J Cancer; 2011 May; 128(9):2020-30. PubMed ID: 20635390
[TBL] [Abstract][Full Text] [Related]
3. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R; Ebel W; Routhier EL; Patel R; Kline JB; Zhang J; Chao Q; Jacob S; Turchin H; Gibbs L; Phillips MD; Mudali S; Iacobuzio-Donahue C; Jaffee EM; Moreno M; Pastan I; Sass PM; Nicolaides NC; Grasso L
Cancer Immun; 2007 Dec; 7():20. PubMed ID: 18088084
[TBL] [Abstract][Full Text] [Related]
5. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.
Tang Z; Feng M; Gao W; Phung Y; Chen W; Chaudhary A; St Croix B; Qian M; Dimitrov DS; Ho M
Mol Cancer Ther; 2013 Apr; 12(4):416-26. PubMed ID: 23371858
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin targeted cancer immunotherapy.
Hassan R; Ho M
Eur J Cancer; 2008 Jan; 44(1):46-53. PubMed ID: 17945478
[TBL] [Abstract][Full Text] [Related]
7. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
Zhang YF; Phung Y; Gao W; Kawa S; Hassan R; Pastan I; Ho M
Sci Rep; 2015 May; 5():9928. PubMed ID: 25996440
[TBL] [Abstract][Full Text] [Related]
8. Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.
Ma J; Tang WK; Esser L; Pastan I; Xia D
J Biol Chem; 2012 Sep; 287(40):33123-31. PubMed ID: 22787150
[TBL] [Abstract][Full Text] [Related]
9. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
Hatterer E; Chauchet X; Richard F; Barba L; Moine V; Chatel L; Broyer L; Pontini G; Bautzova T; Juan F; Calloud S; Bosson N; Charreton M; Masternak K; Buatois V; Shang L
MAbs; 2020; 12(1):1739408. PubMed ID: 32191151
[TBL] [Abstract][Full Text] [Related]
10. The role of mesothelin in tumor progression and targeted therapy.
Tang Z; Qian M; Ho M
Anticancer Agents Med Chem; 2013 Feb; 13(2):276-80. PubMed ID: 22721387
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.
Inami K; Abe M; Takeda K; Hagiwara Y; Maeda M; Segawa T; Suyama M; Watanabe S; Hino O
Cancer Sci; 2010 Apr; 101(4):969-74. PubMed ID: 20100205
[TBL] [Abstract][Full Text] [Related]
12. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan R; Thomas A; Alewine C; Le DT; Jaffee EM; Pastan I
J Clin Oncol; 2016 Dec; 34(34):4171-4179. PubMed ID: 27863199
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin, a novel immunotherapy target for triple negative breast cancer.
Tchou J; Wang LC; Selven B; Zhang H; Conejo-Garcia J; Borghaei H; Kalos M; Vondeheide RH; Albelda SM; June CH; Zhang PJ
Breast Cancer Res Treat; 2012 Jun; 133(2):799-804. PubMed ID: 22418702
[TBL] [Abstract][Full Text] [Related]
15. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.
Chowdhury PS; Viner JL; Beers R; Pastan I
Proc Natl Acad Sci U S A; 1998 Jan; 95(2):669-74. PubMed ID: 9435250
[TBL] [Abstract][Full Text] [Related]
16. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.
Ho M
BioDrugs; 2011 Oct; 25(5):275-84. PubMed ID: 21942912
[TBL] [Abstract][Full Text] [Related]
17. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
18. Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
Sirois AR; Deny DA; Baierl SR; George KS; Moore SJ
PLoS One; 2018; 13(5):e0197029. PubMed ID: 29738555
[TBL] [Abstract][Full Text] [Related]
19. Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody.
Dangaj D; Abbott KL; Mookerjee A; Zhao A; Kirby PS; Sandaltzopoulos R; Powell DJ; Lamazière A; Siegel DL; Wolf C; Scholler N
PLoS One; 2011; 6(12):e28386. PubMed ID: 22163010
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of (111)In labeled antibodies for SPECT imaging of mesothelin expressing tumors.
Misri R; Saatchi K; Ng SS; Kumar U; Häfeli UO
Nucl Med Biol; 2011 Aug; 38(6):885-96. PubMed ID: 21843785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
